The company has completed enrollment in a study testing its delivery technology with semaglutide. Results timing isn't given in the headline report.
Recap by typeshit. Full story at Investing.com.
The Scientist weighs whether GLP-1 drugs could lengthen life and finds the answer still unsettled. Tap through for where the research stands.
The review covers 47 peptides from meat, leather and seafood waste and cites a 12-trial meta-analysis showing a systolic drop of about 5 mmHg, credited to the authors.
Researchers think orexin drugs could expand into ADHD and fatigue the way GLP-1s grew past diabetes. Alkermes reported early ADHD results in 50 adults.
Researchers report in Amino Acids that the peptide blocks HMGA2 at the IL6 promoter in a cell model. The authors note the work is cell culture only, far from any human use.
NYU's Holly Lofton and Harvard's Jennifer Manne-Goehler say trial safety looks similar to other GLP-1s, but warn gray market vials may hold no active drug.
A short PBS clip with a herpetologist on how GLP-1 medications trace back to a lizard.
Loading…